QIBA PET Amyloid Claim 1

A measured change in SUVR of Δ % indicates that a true change has occurred if $\Delta > 8\%$, with 95% confidence.



QIBA PET Amyloid Image Analysis Workstation Needs Based on Claim

- Only have longitudinal claim
 - No need to measure <u>bias</u>, as long as:
 - Same patient, same scanner, same protocol, same analysis, etc.
 - Note: major offsets or constant error still unacceptable and detected by linearity tests (under what conditions)
 - <u>Linearity</u>
 - Is our system linear for a range of SUVRs?
 - <u>Repeatability</u>
 - Can we get the same SUVR multiple times if nothing has changed?

Major Objectives of IAW Conformance

- Test Linearity
 - Will simulate 6 different subjects
- Test Repeatability
 - Will simulate 5 different acquisitions per subject
- "DRO" is therefore a series of 30 different images
- DRO series derived from a <u>single</u> MRI segmentation
 - Therefore we will NOT be testing different brain morphologies
 - Time constraints don't allow more

DRO Series – Simulation of 6 Different Subjects

- Subject 1
 - GM/WM = 0.9
- Subject 2
 - GM/WM = 1.0
- Subject 3
 - GM/WM = 1.1
- Subject 4
 - GM/WM = 1.2
- Subject 5
 - GM/WM = 1.3
- Subject 6
 - GM/WM = 1.4



Segmented DRO - values of GM and WM can be varied

DRO Series – Simulation of 5 Different Acquisitions on Same Subject



GM/WM = 1.4

Uncorrelated Poisson Noise + 6 mm FWHM **Gaussian Blurring**





GM/WM = 1.4

Uncorrelated Poisson Noise + 6 mm FWHM **Gaussian Blurring**

Uncorrelated Poisson

Noise + 6 mm FWHM

Uncorrelated Poisson Noise + 6 mm FWHM **Gaussian Blurring**

Gaussian Blurring











- Subject 6
 - Generate 5 different images by randomly adding clinical-type noise



GM/WM = 1.4



GM/WM = 1.4



Uncorrelated Poisson Noise + 6 mm FWHM **Gaussian Blurring**



GM/WM = 1.4

Example Output – For <u>Single</u> Target Region

Will be one graph for each Target Region if single reference region is used If multiple reference regions, then total graphs = (number of target regions) x (number of reference regions)



IAW Conformance – <u>Target Region 1</u>

SUVR - Truth

Key Points

- <u>Linearity</u>: Profile will state accepted linearity measures (e.g. quadratic term, slope, R², etc.)
- Repeatability: Profile will state acceptable error bars for data points

Typical Regions Used for Target and Reference

Target

- Frontal
- Anterior cingulate
- Posterior cingulate
- Lateral temporal
- Inferior parietal regions
- Occipital cortex

Specify regions that are GM only for this conformance test?

Need to report region mask that were used for target and reference regions by the IAW?

Reference

- Whole cerebellum
- Cerebellar gray matter
- Pons
- Brainstem
- Eroded subcortical white matter
- Composite

The Profile would tell the IAW actor to:

- 1. Fit an ordinary least squares (OLS) regression of the Y_i's on X_i's (blue data points on previous graph). A quadratic term is first included in the model: $Y = \beta_0 + \beta_1 X + \beta_2 X^2$.
- 2. Re-fit a linear model: $Y = \beta_0 + \beta_1 X$ (red dotted line on previous graph). R-squared (R²) shall be >0.90.
- 3. The estimate of B_1 and of B_2 shall be reported as part of the assessment record. see <u>Compliance Statistics Template</u>
- 4. At each measurand (e.g. SUVR) value, calculate the mean and SD.
- 5. Calculate the %RC (<u>formula</u>).
- 6. The %RC shall be $\leq 4\%$.

Sample Size Considerations for Testing RC:

Assumption (due to our Claim): The IAW's RC needs to be <4%.

 With <u>6 SUVR</u> values ("subjects"), and <u>5 realizations</u> ("times") at each, an actor would need to have their <u>RC<2.6%</u> in order to meet the Profile criterion (80% power to show that their RC is <u><</u>4%)

0	pt	io	ns:

# of Subjects (SUVRs)	# of Realizations (Tests per subject)	RC Threshold
6	5	2.6%
7	5	2.8%
9	5	2.9%
11	5	3.0%
6	10	3.1%

Profile: Next Steps and Milestones

- Have current version of DRO read by radiologist (UW and Rathan)
- Make requested changes to DRO based on radiologist feedback
- Constrain what DRO tests in optimal way
 - Single Gaussian filter value for smoothing? (currently set at 6 mm FWHM)
 - Only one patient morphology will be tested (no time to segment another MRI volume)
 - Decide if anatomical regions will be specified
 - Decide if region boundaries will be specified
 - Decide if test needs to report an overlay of the target and reference regions on the DRO
 - MRI will be provided with the DRO series
 - Should multiple realizations include simulation of patient movement?
- Develop limited initial series of DROs and test on IAWs
- Based on feedback, updatee DRO series and Profile IAW Conformance section of Profile